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Background: Salivary gland function is controlled by the salivary reflex, whose efferent arm is composed by the 
parasympathetic and the sympathetic divisions of the autonomic nervous system. Parenchymal injury is the main 
salivary gland involvement of Sjögren’s syndrome and head and neck radiotherapy, but neural damage has been 
reported as well. Recently an intraoral device for electrostimulation of the lingual nerve in vicinity to the lower 
third molar has been introduced. At this point this nerve carries efferent fibers for the innervation of the subman-
dibular, sublingual and several minor salivary glands and afferent fibers of the salivary reflex. Therefore, excita-
tion of these fibers potentially leads to increased secretion of all salivary glands. Thus, the study objective was to 
assess whether comprehensive neural activation by electrostimulation of the lingual nerve carries the potential to 
induce the regeneration of damaged salivary glands.
Material and Methods: The device was tested on three patients with no collectable resting and stimulated secretion 
of saliva during a double blind, sham controlled period of two months and nine open-label months. 
Results: All three subjects developed the capacity to spit saliva, not only in direct response to the electrostimula-
tion but also after free intervals without electrostimulation. In addition, their symptoms of dry mouth severity and 
frequency improved. 
Conclusions: This recovery is probably due to the combined effect of increase in secretory functional gland mass 
and regain of nervous control of the secretory elements and blood vessels. Both are phenomena that would con-
tribute to gland regeneration. 
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Background
Saliva is of outmost importance for oral health and 
quality of life. Lack of saliva causes dry mouth, weak-
ened taste acuity, dental caries and candidiasis, and 
difficulties in speech, mastication and swallowing (1). 
Sjögren ś syndrome and head and neck radiotherapy are 
characterized by salivary gland parenchymal destruc-
tion and hypofunction, but neural damage has been 
reported as well (2,3). Though parasympathomimet-
ics (pilocarpine, cevimeline) are effective sialogogues, 
their use is hampered by adverse effects such as sweat-
ing, diarrhea, urinary urges, bronchoconstriction and 
hypotension. Moreover, due to the co-morbidities in the 
elderly, their use is frequently contraindicated (4).   
Salivary glandular functions are regulated through reflex-
es elicited by alimentary activities. The parasympathetic 
innervation causes the main part of the salivary flow, but 
notably parasympathetic and sympathetic innervations 
interact synergistically by various acinar receptors (Fig. 
1) (5). Furthermore, nerves exert long-term trophic ef-
fects, as illustrated in animal experiments: gland size and 
secretory capacity adapt to prolonged variations in the 
intensity of the reflex stimulation (6). In a recent clini-
cal trial, consisting of a crossover sham-controlled phase 
followed by an open-label phase (7,8), electrostimulation 
of the lingual nerve on one side by an intraoral device 
applied regularly in brief periods, was shown as a safe 
and efficacious way of decreasing oral dryness in a study 
population of about 100 patients with xerostomia of vari-
ous etiologies. Electrostimulation aimed at activating 
not only efferent (preganglionic parasympathetic) nerve 
fibers of the ipsilateral submandibular and the sublingual 
glands but also afferent fibers resulting in global (bilat-
eral) salivary reflex responses (Fig. 2).  
Three patients, a sample of the study population, that had 
no collectable saliva initially, increased their secretory 
capacity over 11 months, at the regular use of the device. 
The clinical results of these non-secreting patients are 
reported, each with a different diagnostic background 
- primary and secondary Sjögren ś syndrome, and head 
and neck radiotherapy. 
Materials and Methods
- Device description
GenNarino™ is an individualized mouthpiece contain-
ing an electronic circuit with a microprocessor, a pair 
of stimulating electrodes and two 3V 30mAmp/h bat-
teries (Fig. 3). The electrodes contact the oral mucosa 
in the mandibular third molar area, close to the lingual 
nerve on one side (Fig. 2). The electrical stimulation is 
of low intensity and not felt by the patient. This feature 
enables an ideal scenario for undertaking double-blind 
sham-controlled studies (9). In this trial the stimulation 
signals were pulse-trains at 5Hz, biphasic, at rectangu-
lar pulses of 1mSec, with an output of 150µA. 
The patient activates and deactivates the electrical 
stimulation by pressing the “ON” and “OFF” buttons 
of the remote control, respectively. An amber light on 
GenNarino that blinks upon activation of the remote 
control ensures that the device is working as intended 
by design. Failure to blink means that the device is not 
functional and needs to be returned, and that a new one 
has to be ordered. 
- Study design
The study was conducted in full accordance with ethi-
cal principles, including the World Medical Association 
Declaration of Helsinki and the additional requirements 
of the countries where the research has been carried 
Fig. 1. Schematic overview of the neural control of salivary gland function. Acinar cells (below) are prompted to produce saliva by neurotrans-
mitters (above) that bind specifically to surface receptors. The parasympathetic arm releases acetylcholine and neuropeptides (i.e. vasoactive 
intestinal peptide, VIP) that bind to muscarinic (M1 and M3) and peptidergic receptors, respectively. The sympathetic neurotransmitter nor-
epinephrine binds to α1- and β1-adrenergic receptors. Fluid secretion is mainly the result of muscarinic and α1-adrenergic activation, whereas 
protein production derives mainly from the stimulation of peptidergic and β1-adrenergic receptors.
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Fig. 2. The upper part (“Anatomical landmarks”) shows the location of the electrostimulation in relation to relevant anatomic 
structures: third molar, lingual nerve, submandibular ganglion and gland, sublingual gland and the excretory duct. It should 
be noted that the figure does not depict neither fibers that detach from the submandibular ganglion in direction to minor sali-
vary glands nor the sensorial origins of the lingual nerve. The lower part (“Neural pathways”) provides an overview of the 
consequences of the lingual nerve electrostimulation (black dashed arrow) on the salivary reflex at the parasympathetic arm. 
The black full arrows represent afferent activity, while all other arrows denote efferent activity, as follows: 
- light blue arrows: fibers going up to the submandibular ganglion (SM ggl),
- purple arrows: fibers going to the otic ganglion (Otic ggl),
- red arrows: fibers originating from the submandibular ganglion and innervating the submandibular (Submand) and 
sublingual (Subling) glands,
- orange arrows: fibers to the minor salivary glands (Minor glands), and
- green arrows: fibers to the parotid gland. 
Dashed light blue, red and orange arrows denote fibers that carry impulses derived from both, direct and reflex stimulation. 
Other abbreviations: n (nerve), mand (mandibular branch), max (maxillary branch), ch (chorda), ggl (ganglion).
The single asterisk indicates that the lingual nerve contributes to minor gland innervation also via Remak ś intralingual 
ganglia in addition to the submandibular ganglion, while the double asterisk denotes that the palatine nerve originates 
from the sphenopalatine ganglion (12).
Note that sympathetic nerves can be expected to act on the glands as well, as an effect of the stimulation of the reflex 
arc. Reflexly elicited sympathetic impulses, originating from the upper thoracic paravertebral sympathetic trunk, reach 
their targets via sympathetic nerve fibers following the arteries of the glands; the relay between pre- and postganglionic 
sympathetic fibers is the superior cervical ganglion. However, the minor glands are thought to lack a sympathetic in-
nervation of their acinar cells (12).
Fig. 3. The GenNarino device with the rectangular electronic 
circuit on its right side and the round battery on the anterior 
part. A pair of stimulating electrodes protrude from the buccal 
surface on the ex treme right side extension (not shown in this 
lingual view-picture). The latter are positioned in such a man-
ner that they are in contact with the oral mucosa in the mandib-
ular third molar area, in the immediate proximity to the lingual 
nerve. As the flange is separated from the mucosal sur face, the 
electrodes don’t prick the tissue.
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out. The study was approved by all ethical boards and 
registered at ClinicalTrials.gov (US National Institutes 
of Health, Identifier: NCT00509808). All study subjects 
gave their informed written consent.
Xerostomia patients were recruited in 14 institutions of 
13 countries. The overall results of this trial have already 
been published (7,8). This paper reports the assessments 
obtained from all the subjects that started the study with 
a salivary flow rate judged as zero and showed up to all 
the follow-up sessions until the 11-month study comple-
tion (n=3).. They were evaluated at Charité Universitäts-
medizin Berlin (Germany), İstanbul Üniversitesi (Tur-
key), and Università di Palermo (Italy). 
This prospective trial was divided in 2 stages. The first 
stage (Stage I) was randomized, sham-controlled, cross-
over and aimed to determine if electrostimulation has 
an additive effect on mechanical stimulation achieved 
by GenNarino’s foreign body effect in the mouth. The 
second stage (Stage II) was open-labeled and aimed to 
assess long-term influence of GenNarino on xerostomia 
parameters. During both stages subjects were instruct-
ed to use the device not more than once every hour but 
otherwise as many times as they liked every day. 
In Stage I, GenNarino was used for 10 minutes at a time 
in either “sham” (mechanical stimulation) or “active” 
(mechanical and electrical stimulation) mode, each 
during one month in a double blind fashion. This time 
period was chosen since it was used in a preliminary 
proof of the principle study, in which the device was 
used in a clinic during 10 minutes (9). The sequence 
of “sham” and “active” use was assigned randomly to 
each patient. Identically looking remote controls were 
assigned to each subject, with pre-coded software com-
mands set for either not activating (“sham”) or activat-
ing (“active”) the electrical stimulation upon pressing 
the “ON” button. Both, patients and investigators, were 
blinded to the type of stimulation (mechanical only or 
mechanical-electrical) schedule. Stage II was open-la-
bel where only “active” devices were used after comple-
tion of Stage I for 9 months to assess the cumulative 
effect of electrostimulation from baseline, throughout 
the “active” month of Stage I until the end of the study. 
At the beginning of the study, together with the Stage I 
randomization, subjects were also randomly allocated 
to use the device during each trimester of Stage II either 
1, 5 or 10 minutes at a time. 
- Outcome measures
The devices were manufactured by the study initiating 
company, Saliwell Ltd (Harutzim, Israel) using impres-
sions taken from the subjects’ dental arches. After base-
line, outcome assessments took place at the end of the 
1st, 2nd, 5th, 8th and 11th month of device use. At each 
follow-up, questionnaires, whole saliva and safety-re-
lated information were collected. The primary outcome 
(xerostomia severity) and patient-centered secondary 
outcomes were measured by a previously validated 
questionnaire (10). This paper reports the assessments 
most directly related to salivary gland function, i.e. rest-
ing and stimulated salivary flow rates and the replies to 
the questions “How dry is your mouth today?” (“dry 
severe”) and “How often does your mouth feel dry?” 
(“dry frequent”). Answers to the question “dry severe” 
were reported using 10 cm long Visual Analogue Scales 
running from the worst condition on the left to the best 
on the right end of the line, and to the question “dry 
frequent”, with possible responses: Always / Frequently 
/ Occasionally / Never, rated 1/2/3/4, respectively).
Resting and stimulated salivary flow rates were assessed 
always at morning hours. Patients were requested to 
take nothing into their mouth for 90 minutes or longer, 
and then to spit during five minutes into containers (F.L. 
Medical, Padova, Italy, catalogue #25174), while avoid-
ing swallowing. The containers were closed immediate-
ly after collection to avoid fluid evaporation. Salivary 
flow was stimulated by chewing a piece of parafilm. Sa-
liva volume was determined gravimetrically (assuming 
a specific gravity of 1.0) (11).
As safety-related secondary outcome measures, vital 
signs (blood pressure and heart rate), changes in health 
condition (as reported by the patients) and oral mucosal 
status were assessed.  
Results
- Subject BG
This 52 year old, Caucasian female suffered from mixed 
collagenosis and myalgia. Serologic laboratory param-
eters were found positive for anti-nuclear antibodies 
and enhanced extracted nuclear antigens. Despite no 
histologic findings of inflammatory foci in a biopsy of 
minor salivary glands from the lower lip submucosal 
tissue, secondary Sjögren’s Syndrome was considered 
to be her diagnosis. During the five years preceding the 
present study, the patient developed symptoms of oral 
dryness, severely interfering with her quality of life.  
At time of admission, the regular medication comprised 
oral intake of pilocarpine (5 mg three times per day) 
which was ceased prior to inclusion into the clinical 
study. Apart from that, the patient took the immuno-
suppressive drug azathioprine 75mg twice daily and 
thyroxine 150µg per day regularly. On month 4 of the 
study, estrogen replacement was prescribed addition-
ally. 
During the study progress, the frequency of using the 
device was reduced from 6 to 5 times daily between 
visits 2 and 3 (corresponding to the blinded active or 
sham device usage period) as well as from 5 to 4 times 
daily between visits 3 and 4. From visit 4 onwards, the 
frequency of using the device was further reduced from 
4 to 3 times daily. Nevertheless, prior to visit 4 the pa-
tient reported frequent subjective feeling of oral dry-
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ness, whereas she reported occasional feeling of oral 
dryness afterwards, despite the reduced frequency of 
using the device.  
- Subject IT
This 62 years old male patient was referred to the Oncol-
ogy Department due to neck swelling. Further to a biop-
sy from nasopharyngeal tissue he was diagnosed with 
undifferentiated nasopharyngeal carcinoma (type 3). 
He received chemotherapy with three doses of 200mg 
cisplatin in 2004. In 2005 he was treated with radio-
therapy at the nasopharyngeal area at a dose of 70Gy in 
28 fractions, and bilaterally to the neck area at a dose of 
50Gy in 28 fractions. He had severe xerostomia during 
the radiotherapy and thereafter. 
He used the device 10-15 times daily throughout the 
study and was not medicated to treat xerostomia. When 
asking to add comments in addition to the structured 
questionnaire he declared that the device is ineffective 
after the one sham month, and the he “cannot live with-
out the device” at the end of the study. Up today, there 
was no cancer recurrence and his stimulated whole sali-
vary flow rate is normal with a value of 1 ml/min.
- Subject PI
This 69 years old female patient had a definitive diag-
nosis of primary Sjögren’s Syndrome, based upon mi-
nor salivary gland biopsy and serological tests. As the 
disease affected severely her quality of life, the patient 
took regularly, in addition to xerogenic and antihyper-
tensive drugs, also antidepressant medication.
At time of admission, the regular medication for 
Sjögren’s syndrome comprised oral intake of pilocar-
pine hydroxychloroquine and topical sialogogues. How-
ever neither pilocarpine nor any other systemic sialo-
gogue were used during the trial. 
During the study period, the frequency of using the de-
vice increased from 2 to 3 times daily between visits 4 
and 5. Subjective feeling of difficulties in swallowing 
and speaking slightly decreased during the study peri-
od, whereas she reported constantly feeling of oral dry-
ness, despite changes of frequency in using the device.  
Summary of findings
Table 1 summarizes the findings of the three subjects. 
In general, the pattern of the oral dryness symptoms 
was: 1) severity of xerostomia seemed to improve from 
Subject/ 
diagnosis Parameter
Randomized controlled stage Open label stage (only active)
Baseline Sham Active Month 5 Month 8 Month 11
BG/sSS†
Month 1 Month 2
Dry severe‡ 1 4 5 4 7 6
Dry frequent§ 2 2 2 2 3 2
RSFR¶ 0 0 12 12 0 14
SSFR†† 0 0 72 14 14 58
IT/RT‡‡
Month 2 Month 1
Dry severe‡ 8 0 5 6 9 9
Dry frequent§ 1 2 2 3 4 4
RSFR¶ 0 0 258 100 100 200
SSFR†† 0 0 294 210 375 400
PI/pSS§§
Month 2 Month 1
Dry severe‡ 1 0 0 1 1 1
Dry frequent§ 1 1 1 1 2 2
RSFR¶ 0 0 0 0 0 2
SSFR†† 0 0 0 1 1 4
Table 1. Summary of the findings of the three subjects.
† sSS: Secondary Sjögren’s Syndrome
‡ “How dry is your mouth today?” VAS score (from 0 -worst situation- to 10 -best situation)
§ “How often does your mouth feel dry?” 1 (always) - 2 (frequently) - 3 (occasionally) - 4 (never)
¶ Resting salivary flow rate, in µl/min
†† Stimulated salivary flow rate, in µl/min
‡‡ RT: radiotherapy
§§ pSS: Primary Sjögren’s Syndrome
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baseline to month 11 for subjects BJ and IT and to re-
main stable for subject PI; 2) frequency of xerostomia 
appeared to improve from baseline to month 11 for sub-
jects IT and PI and remain stable for subject BG; 3) for 
subjects BG and IT the month “active” had better out-
comes, in comparison to the month “sham”, in regards 
to of dryness severity but was similar for all subjects in 
terms of dryness frequency; 4) the trends of subjective 
parameters were roughly correlated with the objective 
ones.
Salivary flow rates of all 3 patients, either resting or 
stimulated by chewing, were 0 at baseline and after one 
month of “sham” device use, whether this month was 
the first follow-up month (subject BJ) or it followed the 
month of “active” device use. Among patients BG and 
IT, resting and stimulated saliva could be collected af-
ter the first month of “active” device use, whether this 
month was the first follow-up month (subject IT) or it 
followed the month of “sham” device use. In subject PI 
a small volume of stimulated saliva could be collected 
at the end of month 5, but unstimulated saliva was only 
collectable at the end of the trial. For all 3 patients, once 
the first time saliva could be collected, stimulated flow 
rate never returned to 0 after using the “active” device. 
In regards to resting saliva, except for the month 8 col-
lection of subject BG, it was always collectable after its 
first appearance upon “active” device utilization.
For all three subjects, no significant changes in the vital 
signs and in the oral mucosal status were detected.
Discussion
While unilateral electrostimulation of the oral mucosa 
on the lingual side of the third molar region was ac-
companied by increases in salivary output and relief 
of xerostomia in the three patients, other consequenc-
es related to lingual nerve activation such as pain and 
taste sensations were not experienced. Thus, through 
the excitation of the lingual nerve, the device is likely 
to (a) trigger the afferent large Aß fibers, which relay 
modalities of touch-pressure, vibration, and possibly 
proprioception and, thus, to evoke the salivary reflex 
engaging different types of salivary glands bilaterally, 
and to (b) stimulate directly the efferent secretomotor 
parasympathetic fibers to the ipsilateral submandibular 
and sublingual glands (12). The device is, however, un-
likely (c) to stimulate the small somatic Aδ and C fibers 
for pain and temperature sensation as the output of the 
device (150µA) is well below the pain tolerance thresh-
old in the alveolar ridge (1500µA), and (d) to stimulate 
the special afferent (taste) components as opposed to the 
taste response that can be evoked by the application of 
electrogustometry on the tongue taste buds (13). 
Previous studies using electrostimulation have either 
aimed at activating only afferent nerves of the glands, 
by a hand-held device placed between the tongue and 
the palate (14), or at activating only the efferent nerve 
of the parotid gland (i.e., the auriculo-temporal nerve), 
by transcutaneous nerve stimulation (TENS) applied to 
the parotid region (15). Thus, direct and simultaneous 
stimulation of both afferent and efferent nerve fibers of 
the salivary reflex did not occur. A further disadvantage 
in those studies was the big size of the devices and the 
evidently unwieldy use of them.
A shortcoming of the present study is its small num-
ber of subjects. Another significant drawback of the 
long term stage (months 3-11) of the current study is 
the lack of comparison with a sham device serving as 
control. Notwithstanding, sham devices exert a me-
chanical stimulation. It is also well known that without 
treatment, salivary gland function and the perception of 
oral wetness are not expected to improve or may even 
worsen within the time frame studied here (16,17).
Although salivary gland hypofunction is not an abso-
lute indicator of the subjective symptoms of xerostomia, 
the patients presently under study shared a pattern of 
parallelism between functional (measured by flow rate) 
and symptomatic (assessed by questionnaire) recovery. 
However, their strength of response was dissimilar, 
with recovery of subject IT being the strongest and that 
of subject PI very poor. Scrutiny of the findings raises a 
series of questions:
1) What is the reason that patient IT had an impressive 
subjective and objective recovery, despite the massive 
damage to the salivary glands as a result of the high-
dosage radiotherapy delivered to treat his malignancy? 
Radiotherapy for nasopharyngeal carcinoma encom-
passes all the salivary glands, damages all gland struc-
tures and causes the most severe gland hypofunction 
and xerostomia (17) and further, regenerative therapy 
of this pathology is an arduous challenge (18). This par-
ticular patient was extremely compliant with the study 
protocol. He used the GenNarino device 10-15 times per 
day throughout the entire study length. Perhaps this in-
tensive and repeated electrostimulation potentiated the 
positive outcome.
2) Why the recovery of subject BG, suffering from sec-
ondary Sjögren’s Syndrome, was much better than for 
subject PI, suffering from primary Sjögren’s Syndrome? 
As the frequency of device usage was similar for both 
patients, it might be interesting to assess an impact of 
the type of underlying disease. In fact, a study found a 
higher frequency of oral symptoms and stronger B cell 
activity (autoantibody production and lymphocyte in-
filtration) in primary Sjögren’s Syndrome compared to 
secondary Sjögren’s Syndrome (19). 
The probable cause of the reappearance of collectable 
salivary output in the three patients is the re-establish-
ment of functional neuro-effector junctions accompa-
nied with regeneration of gland tissue as judged by pre-
clinical studies. In general parasympathetic innervation 
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is required for salivary organogenesis by maintenance 
of the epithelial progenitor cell population (20). Long-
term studies on adult animals show the importance of 
the parasympathetic nerves in the recovery of salivary 
glands subjected to atrophic influences: (a) upon para-
sympathetic denervation and allowing time for re-in-
nervation, the atrophic glands gain in weight and the re-
flexly elicited secretory response returns (21,22) and (b) 
upon extreme atrophy, such as after a transient period 
of duct-ligation, while providing for the maintenance of 
the parasympathetic innervation, salivary glands retain 
the ability to regenerate (23).
By electrical stimulation of the parasympathetic in-
nervation or by reflexly elicited parasympathetic nerve 
activity through mastication, the mitotic activity of 
the glands increases (24-27). Though, the sympathetic 
innervation seems of minor importance for the gland 
size, as judged by denervation experiments (28), there 
are reports of increases in mitotic activity and  cell size 
upon sympathetic stimulation (29,30).  Experimentally, 
treatment with a β-adrenergic receptor agonist causes 
a profound weight-gain without being accompanied by 
increased secretory capacity (31). 
Though parasympathomimetics are traditionally used 
in the clinic to stimulate the glands, experiments show 
that their excitation of the muscarinic receptors does 
not restore the marked reduction in gland size of the 
parasympathetically denervated gland, neither do para-
sympatholytics (like atropine ) mimic the weight fall 
caused by the denervation, findings showing that the 
gland size is not regulated by muscarinic receptors, but 
rather by parasympathetic neuropeptide-transmitters 
and (or) neuro-trophic factors of which we know little 
about (32).
Since the functional regeneration of the glands is like-
ly to depend on an interplay between gland tissue and 
nerves, it is of interest to note, as judged from other 
experimental models, that electrical nerve stimulation 
promote the repair of damaged nerves (33,34).
Conclusions
Since the specific factors controlling gland size and 
glandular activities are far from fully understood, com-
prehensive nerve stimulation as achieved by lingual 
nerve electrostimulation seems to be an excellent way to 
reactivate and regenerate the glands, while at the same 
time avoiding adverse effects. Bilateral stimulation of 
the lingual nerve could enhance the effect even more. 
References
1. Aliko A, Wolff A, Dawes C, Aframian D, Proctor G, Ekström J, 
et al. World Workshop on Oral Medicine VI: clinical implications of 
medication-induced salivary gland dysfunction. Oral Surg Oral Med 
Oral Pathol Oral Radiol. 2015;120:185-206. 
2. Mathews SA, Kurien BT, Scofield RH. Oral Manifestations of 
Sjögren’s Syndrome. J Dent Res. 2008;87:308-18.
3. Redman RS. On approaches to the functional restoration of sali-
vary glands damaged by radiation therapy for head and neck cancer, 
with a review of related aspects of salivary gland morphology and 
development. Biotech Histochem. 2008;83:103–30.
4. Villa A, Wolff A, Aframian D, Vissink A, Ekström J, Proctor G, 
et al. World Workshop on Oral Medicine VI: a systematic review of 
medication-induced salivary gland dysfunction: prevalence, diagno-
sis, and treatment. Clin Oral Invest. 2015;19:1563–80.
5. Villa A, Wolff A, Narayana N, Dawes C, Aframian DJ, Lynge Ped-
ersen AM, et al. World Workshop on Oral Medicine VI: a systematic 
review of medication-induced salivary gland dysfunction. Oral Dis. 
2016;22:365–82.
6. Ekström J. Degeneration secretion and supersensitivity in sali-
vary glands following denervations, and the effects on choline 
acetyltransferase activity. In: Garrett JR, Ekström J, Anderson LC, 
eds. Neural mechanisms of salivary gland secretion. Basel: Karger; 
1999:166-84.
7. Strietzel FP, Lafaurie GI, Bautista Mendoza GR, Alajbeg I, Pejda 
S, Vuletic L, et al. Efficacy and Safety of an Intraoral Electrostimula-
tion Device for Xerostomia Relief. A Multicenter, Randomized Trial. 
Arthritis Rheum. 2011;63:180–90.
8. Alajbeg I, Falcão DP, Tran SD, Martín-Granizo R, Lafaurie GI, 
Matranga D, et al. Intraoral electrostimulator for xerostomia relief: a 
long-term, multicenter, open-label, uncontrolled, clinical trial. Oral 
Surg Oral Med Oral Pathol Oral Radiol. 2012;113:773–81.
9. Strietzel FP, Martin-Granizo R, Fedele S, Lo Russo L, Mignogna 
M, Reichart PA, et al. Electrostimulating device in the management 
of xerostomia. Oral Dis. 2007;13:206-13.
10. Pai S, Ghezzi EM, Ship JA. Development of a Visual Ana-
logue Scale questionnaire for subjective assessment of salivary 
dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 
2001;91:311-6.
11. Vissink A, Wolff A, Veerman ECI. Saliva collectors. In: Wong 
DT, ed. Salivary Diagnostics. 1st ed. Ames: Wiley-Blackwell; 
2008:37-59.
12. Ekström J, Khosravani N, Castagnola M, Messana I. Saliva and 
the control of its secretion. In: Ekberg O, ed. Dysphagia: diagnosis 
and treatment. Berlin:Springer; 2012:19–47.
13. Nakashima Y, Kimoto S, Ogawa T, Furuse N, Ono M, Kawai Y. 
Characteristics of the pain tolerance threshold induced by electrical 
stimulation of the alveolar ridge. Clin Exp Dent Res. 2016;1:80-6.
14. Talal N, Quinn JH, Daniels TE. The clinical effects of electro-
stimulation on salivary function of Sjögren’s syndrome patients. A 
placebo controlled study. Rheumatol Int. 1992;12:43-5.
15. Hargitai IA, Sherman RG, Strother JM. The effects of electro-
stimulation on parotid saliva flow: A pilot study. Oral Surg Oral Med 
Oral Pathol Oral Radiol Endod. 2005;99:316-20.
16. Pijpe J, Kalk WW, Bootsma H, Spijkervet FK, Kallenberg CG, 
Vissink A. Progression of salivary gland dysfunction in patients with 
Sjögren’s syndrome. Ann Rheum Dis. 2007;66:107-12.
17. Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, 
Davies AN, et al. A systematic review of salivary gland hypofunc-
tion and xerostomia induced by cancer therapies: prevalence, sever-
ity and impact on quality of life. Support Care Cancer. 2010;18:1039-
60.
18. Lombaert I, Movahednia MM, Adine C, Ferreira JN. Concise Re-
view: Salivary Gland Regeneration: Therapeutic Approaches from 
Stem Cells to Tissue Organoids. Stem Cells. 2017;35:97–105.
19. Hernández-Molina G, Avila-Casado C, Cárdenas-Velázquez F, 
Hernández-Hernández C, Calderillo ML, Marroquín V, et al. Simi-
larities and differences between primary and secondary Sjögren’s 
syndrome. J Rheumatol. 2010;37:800-8.
20. Knox SM, Lombaert IM, Reed X, Vitale-Cross L, Gutkind JS, 
Hoffman MP. Parasympathetic innervation maintains epithelial pro-
genitor cells during salivary organogenesis. Science. 2010;329:1645–
7.
21. Ekström J, Emmelin N. Reinnervation of the denervated parotid 
gland of the cat. Q J Exp Physiol Cogn Med Sci. 1974;59:1-9.
22. Zhang SE, Su YX, Zheng GS, Liang YJ, Lia GQ. Reinnervated 
Med Oral Patol Oral Cir Bucal. 2018 Sep 1;23 (5):e552-9.                                                                                                                                                         Device for salivary gland regeneration
e559
nerves contribute to the secretion function and regeneration of dener-
vated submandibular glands in rabbits. Eur J Oral Sci. 2014;122:372-
81.
23. Proctor GB, Carpenter GH. Salivary secretion: mechanism and 
neural regulation. Monogr Oral Sci. 2014;24:14-29.
24. Nilsson BO, Rosengren E, Ekström J. Effects of stimulation of 
the parasympathetic and sympathetic innervations in bursts on the 
syntheses of polyamines, DNA and protein in salivary glands of the 
rat: non-adrenergic, non-cholinergic responses. Acta Physiol Scand. 
1991;143:161-8.
25. Schneyer CA, Humphreys-Beher MG, Hall HD, Jirakulsomchok 
D. Mitogenic activity of rat salivary glands after electrical stimula-
tion of parasympathetic nerves. Am J Physiol. 1993;264:G935-8.
26. Ekström J, Havel Engdahl G, Reinhold A. Parasympathetic non-
adrenergic, non-cholinergic-induced protein synthesis and mitogen-
ic activity in rat parotid glands. Exp Physiol. 2000;85:171-6.
27. Ekström J, Reinhold AC. Influence of parasympathetic non-ad-
renergic, non-cholinergic mechanisms on [3H]thymidine uptake in 
rat parotid salivary glands in response to mastication following upon 
a liquid regimen. Arch Oral Biol. 2001;46:1151-5.
28. Ekström J. Role of nonadrenergic, noncholinergic autonomic 
transmitters in salivary glandular activities in vivo. In: Garrett JR, 
Ekström J, Anderson LC, eds. Neural mechanisms of salivary gland 
secretion. Basel: Karger; 1999:94-130.
29. Muir TC, Pollock D, Turner CJ. The effects of electrical stim-
ulation of the autonomic nerves and of drugs on the size of sali-
vary glands and their rate of cell division. J Pharmacol Exp Ther. 
1975;195:372-81.
30. Ekström J, Sayardoust S, Cevik H. Nitric oxide-dependent mitot-
ic activity in salivary glands of the rat upon sympathetic stimulation. 
Arch Oral Biol. 2004; 49:889-94.
31. Ohlin P. Effects of isoprenaline treatment on secretory responses 
and respiratory enzymes of the submaxillary gland of the rat. J Oral 
Ther Pharmacol. 1966;3:190-3.
32. Calafat M, Larocca L, Roca V, Hauk V, Pregi N, Nesse A, et al. 
Vasoactive intestinal peptide inhibits TNF-alpha-induced apoptotic 
events in acinar cells from nonobese diabetic mice submandibular 
glands. Arthritis Res Ther. 2009;11:R53.
33. Foecking EM, Fargo KN, Coughlin LM, Kim JT, Marzo SJ, Jones 
KJ. Single session of brief electrical stimulation immediately follow-
ing crush injury enhances functional recovery of rat facial nerve. J 
Rehabil Res Dev. 2012;49:451-8.
34. Zhu N, Zhang C, Li Z, Meng Y, Feng B, Wang X, et al. Experi-
mental study on the effect of electrostimulation on neural regenera-
tion after oculomotornerve injury. J Mol Neurosci. 2014;54:639-52.
Acknowledgements
GenNarino was developed in an EU-funded R&D project (IST-2001-
37409). Saliwell Ltd. provided all the devices.
Conflict of Interest
The authors have declared that no conflict of interest exist.
